Chordate Medical Holding AB (publ) (CMH.ST)
SEK 12.6
(-1.18%)
SEK 12.6
(-1.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 21.95 Million SEK | 17.78% |
| 2022 | 18.64 Million SEK | -57.69% |
| 2021 | 44.06 Million SEK | 41.15% |
| 2020 | 31.21 Million SEK | 65.58% |
| 2019 | 18.85 Million SEK | -10.74% |
| 2018 | 21.12 Million SEK | -27.55% |
| 2017 | 29.15 Million SEK | -29.11% |
| 2016 | 41.12 Million SEK | -13.62% |
| 2015 | 47.6 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 34.48 Million SEK | 57.05% |
| 2024 Q2 | 26.65 Million SEK | -22.7% |
| 2023 Q1 | 42.49 Million SEK | 127.98% |
| 2023 Q2 | 35.16 Million SEK | -17.25% |
| 2023 Q3 | 29.24 Million SEK | -16.85% |
| 2023 FY | 21.95 Million SEK | 17.78% |
| 2023 Q4 | 21.95 Million SEK | -24.92% |
| 2022 Q3 | 23.69 Million SEK | -21.35% |
| 2022 FY | 18.64 Million SEK | -57.69% |
| 2022 Q1 | 36.3 Million SEK | -17.61% |
| 2022 Q2 | 30.13 Million SEK | -17.0% |
| 2022 Q4 | 18.64 Million SEK | -21.33% |
| 2021 FY | 44.06 Million SEK | 41.15% |
| 2021 Q4 | 44.06 Million SEK | 90.11% |
| 2021 Q3 | 23.17 Million SEK | 13.47% |
| 2021 Q2 | 20.42 Million SEK | -17.01% |
| 2021 Q1 | 24.61 Million SEK | -21.16% |
| 2020 Q2 | 15.76 Million SEK | -18.05% |
| 2020 FY | 31.21 Million SEK | 65.58% |
| 2020 Q3 | 23.94 Million SEK | 51.89% |
| 2020 Q4 | 31.21 Million SEK | 30.37% |
| 2020 Q1 | 19.23 Million SEK | 2.03% |
| 2019 Q4 | 18.85 Million SEK | -8.23% |
| 2019 Q1 | 18.87 Million SEK | -10.65% |
| 2019 FY | 18.85 Million SEK | -10.74% |
| 2019 Q2 | 18.88 Million SEK | 0.08% |
| 2019 Q3 | 20.54 Million SEK | 8.77% |
| 2018 Q1 | 27.03 Million SEK | -7.26% |
| 2018 FY | 21.12 Million SEK | -27.55% |
| 2018 Q4 | 21.12 Million SEK | -15.75% |
| 2018 Q3 | 25.07 Million SEK | -31.66% |
| 2018 Q2 | 36.68 Million SEK | 35.69% |
| 2017 Q2 | 36.67 Million SEK | -13.59% |
| 2017 FY | 29.15 Million SEK | -29.11% |
| 2017 Q3 | 30.79 Million SEK | -16.03% |
| 2017 Q1 | 42.44 Million SEK | 3.21% |
| 2017 Q4 | 29.15 Million SEK | -5.34% |
| 2016 FY | 41.12 Million SEK | -13.62% |
| 2016 Q4 | 41.12 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | 47.6 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | 65.086% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 99.332% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 99.332% |
| Arcoma AB | 81.96 Million SEK | 73.213% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 96.785% |
| BICO Group AB (publ) | 10.19 Billion SEK | 99.785% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 97.092% |
| CellaVision AB (publ) | 928.71 Million SEK | 97.636% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | 61.965% |
| C-Rad AB (publ) | 404 Million SEK | 94.565% |
| Duearity AB (publ) | 15.14 Million SEK | -44.978% |
| Dignitana AB (publ) | 44.83 Million SEK | 51.026% |
| Episurf Medical AB (publ) | 104.3 Million SEK | 78.95% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.96% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | 78.609% |
| Iconovo AB (publ) | 128.07 Million SEK | 82.858% |
| Integrum AB (publ) | 164.85 Million SEK | 86.682% |
| Luxbright AB (publ) | 40.68 Million SEK | 46.038% |
| Mentice AB (publ) | 322.52 Million SEK | 93.193% |
| OssDsign AB (publ) | 356.38 Million SEK | 93.839% |
| Paxman AB (publ) | 167.12 Million SEK | 86.863% |
| Promimic AB (publ) | 92.87 Million SEK | 76.36% |
| Qlife Holding AB (publ) | 39.04 Million SEK | 43.77% |
| SciBase Holding AB (publ) | 64.33 Million SEK | 65.873% |
| ScandiDos AB (publ) | 81.47 Million SEK | 73.052% |
| Sectra AB (publ) | 3.21 Billion SEK | 99.316% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 97.835% |
| Senzime AB (publ) | 433.54 Million SEK | 94.936% |
| SpectraCure AB (publ) | 144.83 Million SEK | 84.841% |
| Stille AB | 804.89 Million SEK | 97.272% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 99.866% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 99.0% |